BioInvent International AB logo

BINV BTA - BioInvent International AB News Story

SEK1.7 0.0  0.0%

Last Trade - 12/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £285.1m
Enterprise Value £150.1m
Revenue £11.8m
Position in Universe th / 1838

BRIEF-Bioinvent's Partner Oncurious NV Presents Phase I Data On TB-403

Mon 12th April, 2021 6:35am
April 12 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT'S PARTNER ONCURIOUS NV PRESENTS PHASE I DATA ON
TB-403
IN PEDIATRIC CANCER
    * CONCLUSION FROM PHASE I STUDY IS THAT RESULTS WARRANT
FURTHER
EVALUATION OF TB-403 IN PEDIATRIC SUBJECTS WITH RELAPSED OR
REFRACTORY MEDULLOBLASTOMA (MB)

Source text for Eikon:  ID:nWkrTzJpH 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.